Sizable pipeline characterized by both high growth and attrition
Parkinson's disease is predominantly treated with longstanding and mature therapies such as levodopa and the dopamine agonists, pramipexole and ropinirole. The market is therefore dominated by generics, with Teva's Azilect (rasagiline) being the last lucrative drug indicated for all Parkinson's disease patients.
Drug developers have responded by introducing new treatment options with clearly defined positions in the market, typically as an option for reducing motor fluctuations alongside levodopa therapy.
The Parkinson's disease pipeline is characterized by a high level of both growth and attrition. The vast majority of Parkinson's disease pipeline candidates are in the preclinical stages of development, however, many programs fail to progress into later stages.
Future clinical trials should aim to target a defined patient population. Clinical trials face difficulties including a high placebo response and poor recruitment of patients. The long duration and slow progressive course of the disease are key factors resulting in clinical trials requiring an extensive amount of resources.